A total of 1655 SLE patients receiving the JAK1/2 inhibitor baricitinib at 4 mg or 2 mg for up to 3.5 years did not experience increased adverse events compared with those receiving placebo, yet the incidence of venous thromboembolism did not increase (95). The gene discussed is JAK1; the disease is systemic lupus erythematosus.